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We	studied	 the	possible	 association	between	patient	 age	
and	sex,	clinical	presentation,	Streptococcus pneumoniae 
serotype,	 antimicrobial	 resistance,	 and	 death	 in	 invasive	
pneumococcal	 disease	 cases	 reported	 by	 17	 European	
countries	during	2010.	The	study	sample	comprised	2,921	
patients,	of	whom	56.8%	were	men	and	38.2%	were	>65	
years	of	age.	Meningitis	occurred	in	18.5%	of	cases.	Death	
was	 reported	 in	264	 (9.0%)	cases.	Older	age,	meningitis,	
and	 nonsusceptibility	 to	 penicillin	 were	 significantly	 asso-
ciated	 with	 death.	 Non–pneumococcal	 conjugate	 vaccine	
(PCV)	serotypes	among	children	<5	years	of	age	and	7-va-
lent	PCV	serotypes	among	persons	5–64	years	of	age	were	
associated	with	increased	risk	for	death;	among	adults	>65	
years	of	age,	risk	did	not	differ	by	serotype.	These	findings	
highlight	 differences	 in	 case-fatality	 rates	 between	 sero-
types	and	age;	thus,	continued	epidemiologic	surveillance	
across	all	 ages	 is	 crucial	 to	monitor	 the	 long-term	effects	
of	PCVs.
Streptococcus pneumoniae causes severe invasive dis-ease that results in considerable illness and death. The 
incidence of invasive pneumococcal disease (IPD) is high-
er during the early years of life and among elderly persons 
(1). Geographic and ethnic differences also exist (1,2). En-
vironmental factors (i.e., ambient temperature, humidity, 
and air pollution) affect IPD incidence (3,4). IPD has also 
been related to recent respiratory viral infection (4).
The ability of the different S. pneumoniae serotypes 
to cause disease has been related to serotype-specific char-
acteristics and the molecular size of the capsular polysac-
charide and chemical composition, among other factors 
(5). Therefore, it seems plausible that different serotypes 
exhibit different virulence and propensity to cause certain 
clinical presentation (5).
Brueggemann et al. studied the invasive disease poten-
tial of different S. pneumoniae serotypes (6). They concluded 
that so-called “highly invasive” serotypes (including 4, 1, 
14, 18C, and 7F), convey a higher risk for invasive disease 
than do the “low invasive” serotypes (including 3, 15B/C, 
and 6B), which are more frequently isolated as colonizers 
(7). Furthermore, serotype distribution varies with patient 
age, both in disease and in nasopharyngeal colonization 
(2,8–10). However, evidence exists that pneumococcal 
invasiveness does not necessarily mean lethality (7). Low 
invasive serotypes usually account for higher case-fatality 
rates (CFRs).
The availability of 7-valent, 10-valent, and 13-va-
lent pneumococcal conjugate vaccines (PCV7, PCV10, 
and PCV13, respectively) and their introduction as part 
of national immunization schedules have contributed to 
reducing illnesses and death from IPD (10–12). Neverthe-
less, the subsequent replacement of vaccine serotypes by 
nonvaccine serotypes is an accepted and global phenom-
enon (13,14).
The incidence of drug- and multidrug-resistant S. 
pneumoniae strains is increasing worldwide (15). Antimi-
crobial use and abuse is a main driver for the emergence of 
antimicrobial resistance in respiratory pathogens. Persons 
who carry (nasopharyngeal colonization), and hence share 
the potential to transmit resistant pneumococci, also are 
more susceptible to IPD caused by resistant strains (16).
Monitoring antimicrobial resistance trends and sero-
type distribution is paramount because this information 
is essential in helping to determine risk factors and opti-
mizing the appropriate clinical management of cases and 
public health interventions. We studied the possible asso-
ciation between age, sex, serotype, clinical presentation, 
antimicrobial resistance, and death among persons reported 
to have IPD in European countries during 2010.
Materials and Methods
Data
IPD data derived from passive national surveillance case 
notification systems were collected during 2010 by 26 Eu-
ropean Union (EU)/European Economic Area countries 
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(Austria, Belgium, Bulgaria, Cyprus, Czech Republic, 
Denmark, Estonia, Finland, France, Greece, Hungary, Ice-
land, Ireland, Italy, Latvia, Lithuania, Malta, Netherlands, 
Norway, Poland, Romania, Slovakia, Slovenia, Spain, 
Sweden, and United Kingdom); data were submitted to 
The European Surveillance System. The platform of The 
European Surveillance System is a metadata-driven system 
for the collection, validation, cleaning, and analysis of data 
hosted by the European Centre for Disease Prevention and 
Control. Surveillance systems differ across Europe, and 
data were reported with varying levels of completeness. 
Countries reported only laboratory-confirmed cases based 
on the EU 2008 case definition.
Study Sample
The study sample was the subsample of cases for which in-
formation was available about both serotype and outcome 
(Figure 1). The sample represents data from 17 European 
countries (Table 1).
Study Variables
An episode of IPD was defined as the isolation of a strain or 
detection of nucleic acid or antigen of S. pneumoniae from 
a normally sterile site. Countries reported IPD outcome ac-
cording to their national surveillance and guidelines. The 
following age groups were defined for the study: <5 years, 
5–64 years, and >65 years. For purpose of this analysis, 
clinical presentation was recoded as “meningitis” and “non-
meningitis.” Clinical presentation was grouped on the basis 
of a literature review (5), which suggested that meningitis 
and nonmeningitis had different degrees of severity and con-
veyed different rates of death.
Serotypes were grouped into 3 categories: PCV7 se-
rotypes (serotypes in PCV7: 4, 6B, 9V, 14, 18C, 19F, and 
23F), PCV13-specific serotypes (serotypes in PCV13 but 
not in PCV7: 1, 3, 5, 6A, 7F, and 19A), and non-PCV sero-
types (serotypes not in any PCV). Results of antimicrobial 
susceptibility testing to penicillin and erythromycin were 
reported as “susceptible,” “intermediate,” or “resistant” by 
the countries according to their national standards and pro-
tocols. Therefore, information was not available about the 
breakpoints and guidelines used for antimicrobial suscepti-
bility testing in each country. For example, in the European 
Antimicrobial Resistance Surveillance Network report for 
2010 (17), 66% of reporting laboratories in Europe used 
Clinical and Laboratory Standards Institute standards, 
whereas 29% applied the European Committee on Antimi-
crobial Susceptibility Testing guidelines.
For this study, we redefined the variable to include just 
2 categories: “susceptible” (cases reported as susceptible 
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Figure 1.	Flow	of	invasive	pneumococcal	disease	cases	through	
the	study,	Europe,	2010.	*Sex	was	unknown	for	1	patient.	AST,	
antimicrobial	susceptibility	testing;	PCV,	pneumococcal	conjugate	
vaccine;	PCV7,	7-valent	PCV;	PCV13,	13-valent	PCV;	TESSy,	
The	European	Surveillance	System.
 
Table 1. Characteristics	of	patients	with	invasive	pneumococcal	
disease,	Europe,	2010* 
Characteristic 
No.	cases	(%	of	total),	
N	=	17,549 
Sample	size,	no.	
(%), n = 2,921† 
Sex   
 F 7,915	(45.3) 1,257	(43.2) 
 M 9,565	(54.7) 1,651	(56.8) 
Age	group,	y   
 <5 1,980	(11.3) 570	(19.7) 
 5–64 7,819	(44.7) 1,222	(42.1) 
 >65 7,684	(44.0) 1,108	(38.2) 
Outcome   
 Nonfatal 4,146	(89.4) 2,657	(91.0) 
 Fatal 491	(10.6) 264	(9.0) 
Clinical	presentation   
 Nonmeningitis 6,047	(79.4) 1,722	(81.5) 
 Meningitis 1,572 (20.6) 391	(18.5) 
Serotype   
 PCV13-specific‡ 4,185	(42.1) 1,235	(42.7) 
 PCV7 1,772	(17.8) 517	(17.9) 
 Non-PCV 3,989	(40.1) 1,137	(39.4) 
Antimicrobial	susceptibility  
 Penicillin   
  Susceptible 8,420	(91.1) 1,949	(94.1) 
  Nonsusceptible§ 827	(8.9) 122	(5.9) 
 Erythromycin   
  Susceptible 6,911	(82.5) 1,573	(76.4) 
  Nonsusceptible 1,471	(17.5) 486	(23.6) 
*Numbers	do	not	add	to	the	total	in	each	category	because	of	missing	
data.	See	Figure	1.	PCV,	pneumococcal	conjugate	vaccine;	PCV7,	7-
valent	PCV;	PCV13,	13-valent	PCV. 
†Defined	as	patients	for	whom	information	was	available	about	serotype	
and	outcome. 
‡Serotypes	contained	in	PCV13	but	not	in	PCV7. 
§Either	resistant	or	intermediate	resistance. 
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by the countries) and “nonsusceptible” (intermediate and 
resistant), both for penicillin and erythromycin. Methods 
for the characterization of isolates and for antimicrobial 
susceptibility testing are provided in detail in the 2010 IPD 
enhanced surveillance report by the European Centre for 
Disease Prevention and Control (18).
Statistical Analysis
Categorical variables are presented as number of cases and 
percentages. We used the Pearson χ2 test to compare the 
proportion of deaths by PCV7, PCV13-specific, and non-
PCV serotypes; the proportion of deaths by the defined 
age groups and by sex; the proportion of deaths by clinical 
presentation; and the proportion of deaths in antimicrobial-
susceptible and -nonsusceptible cases, according to antimi-
crobial drug type. We used the Fisher exact test to analyze 
the association between penicillin-susceptible/penicillin-
nonsusceptible IDP and outcome for patients <5 years of 
age and non-PCV serotypes and to assess differences be-
tween penicillin-susceptible/penicillin-nonsusceptible cas-
es and outcome for serotype 35B. In addition, we assessed 
the associations between each serotype and death using a 
generalized linear model with log-link function. This anal-
ysis was performed for the 28 serotypes that accounted for 
up to 80% of cases with fatal outcomes; each individual 
serotype was also compared with all the others.
Univariable analysis was performed for the 264 fatal 
cases to identify factors associated with a fatal outcome. 
To test the association between age, serotype, clinical pre-
sentation, and death, a generalized linear model with robust 
SEs accounting for the country effect was fitted because 
data came from different national surveillance systems 
and vaccination policies and practices differ widely across 
Europe. We studied the role of variables as potential con-
founders/modifiers, but only age was statistically signifi-
cant. Age was an effect modifier of the association between 
serotype and risk for death, and thus the analysis was strati-
fied by age group.
We also conducted regression analysis. The regression 
model comprised factors that were significant by univari-
able analysis and that had previously been hypothesized to 
affect IPD CFRs.
All p values were 2 tailed, and statistical significance 
was defined as p<0.05. We conducted statistical analy-
ses by using STATA 12.0 (StataCorp, College Station, 
TX, USA).
Results
Case Characteristics
In 2010, the European countries reported 22,565 IPD cases. 
Of these, information was available about laboratory vari-
ables for 17,549 cases (Figure 1); outcome was known 
for 4,637 of these. The study sample comprised 2,921 
cases for which information was available about serotype 
and outcome.
A total of 56.8% of cases (Table 1) occurred in men, 
and 38.2% of cases were among adults >65 years of age. 
Children <5 years of age accounted for 19.7% of cases. 
A total of 264 (9.0%) persons died. Meningitis occurred 
in 18.5% of cases. PCV13-specific serotypes (1, 3, 5, 6A, 
7F, 19A) accounted for 42.7% of cases. Nonsusceptibility 
(intermediate + resistant) to penicillin was reported in 122 
(5.9%) of 2,071 cases; nonsusceptibility to erythromycin 
was reported in 486 (23.6%) of 2,059 cases (Table 1).
PCV13-specific serotypes caused 57.7% (p<0.001) of 
cases among children <5 years of age (Figure 2). Non-PCV 
serotypes accounted for 48.0% of cases among adults >65 
years of age. Meningitis cases were predominantly caused 
by non-PCV serotypes (41.4%, p<0.001) (Figure 2). Non-
susceptibility to penicillin was highest among PCV7 sero-
types (64.8%, p<0.001) (Figure 2).
The Pearson χ2 analysis (Table 2) demonstrated a lack 
of statistical association between sex and death (p = 0.631). 
The CFR was highest for adults >65 years of age (13.7%, 
p<0.001); 2.3% of children <5 years of age died.
Clinical presentation was associated with death. The 
CFR for persons with meningitis was 15.9% compared 
with 8.8% for those without meningitis (p<0.001).
Death was also associated with nonsusceptibility to 
penicillin. Death occurred in 13.1% of cases in which S. 
pneumoniae was not susceptible to penicillin (p = 0.010) 
(Table 2). Nonsusceptibility to erythromycin was not sig-
nificantly associated with death (p = 0.837).
We determined the association between individual 
serotype and death (Table 3). Serotype 35B (relative 
risk [RR] 4.98, 95% CI 2.49–9.95), serotype 4 (RR 2.03, 
95% CI 1.04–3.95), and serotype 11A (RR 1.97, 95% CI 
1.33–2.94) were most associated with death. Serotype 3 
(RR 1.39, 95% CI 0.88–2.21) accounted for the highest 
number and the highest percentage (13.3%) of serotype-
specific deaths, but the association with death was not sta-
tistically significant (p = 0.161). In contrast, for serotype 
1 (RR 0.25, 95% CI 0.13–0.48) and serotype 5 (RR 0.15, 
95% CI 0.09–0.26), the association with death was signifi-
cant. Subanalysis of the association between susceptibility 
to penicillin and outcome for serotype 35B found no sig-
nificant differences in risk for death between susceptible 
and nonsusceptible cases.
Risk Factors for IPD-Associated Death
Univariable analysis showed differences between non-
fatal and fatal cases (Table 4). Persons 5–64 years of 
age (RR 3.55, 95% CI 1.66–7.61) and >65 years of age 
(RR 4.79, 95% CI 3.08–11.76) had a higher risk for death 
than did children <5 years of age. In the univariable 
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analysis, meningitis (RR 1.81, 95% CI 1.25–2.61, p = 
0.002) was significantly associated with death. PCV7 
serotypes were also significantly associated with death 
(RR 2.18, 95% CI 1.06–4.48, p = 0.034). Conversely, non-
PCV serotypes were not associated with death (RR 1.47, 
95% CI 0.94–2.28).
Nonsusceptibility to penicillin was associated with in-
creased risk for death (RR 1.91, 95% CI 1.16–3.13). Non-
susceptibility to erythromycin was not significantly associ-
ated with death (RR 1.04, 95% CI 0.84–1.29).
Our comparison of susceptibility to penicillin and out-
come for clinical presentation showed that the association 
with the outcome remained statistically significant only for 
meningitis cases (RR 1.82, 95% CI 1.27–2.62, p = 0.001). 
These factors were not associated with nonmeningitis cases 
(RR 1.31, 95% CI 0.28–6.01).
Age was an effect modifier. In the stratified analysis, 
we found that among children <5 years of age, risk for 
death from non-PCV serotypes increased (RR 3.68, 95% 
CI 1.27–10.69) (Table 5), whereas among persons 5–64 
years of age, PCV7 serotypes conveyed the highest risk 
for death (RR 2.68, 95% CI 1.37–5.23). Among adults >65 
years of age, risk for death among the serotypes did not 
differ significantly.
We analyzed the association between susceptibility to 
penicillin and outcome for non-PCV serotypes. Children 
<5 years of age showed no differences between susceptible 
and nonsusceptible cases.
Discussion
Our analysis of IPD surveillance data from Europe in 2010 
unveiled a significant association between death and older 
age, meningitis, serotypes contained in PCV7, and non-
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Table 2. Associations	between	invasive	pneumococcal	disease	
study	variables	and	death,	Europe,	2010* 
Variable 
Outcome 
p value† 
Nonfatal,	no.	
(%) 
Fatal,	no.	
(%) 
Sex    
 F 1,147	(91.3) 110	(8.8) 0.631 
 M 1,498	(90.7) 153	(9.3)  
Age	group,	y    
 <5 557	(97.7) 13	(2.3)  
 5–64 1,123	(91.9) 99	(8.1) <0.001 
 >65 956	(86.3) 152	(13.7)  
Clinical	presentation    
 Nonmeningitis 1,571	(91.2) 151	(8.8) <0.001 
 Meningitis 329	(84.1) 62	(15.9)  
Serotype    
 PCV13-specific‡ 1,155	(93.5) 80	(6.5) <0.001 
 PCV7 444	(85.9) 73	(14.1)  
 Non-PCV 1,028	(90.5) 111	(9.5)  
Antimicrobial	susceptibility   
 Penicillin    
  Susceptible 1,815	(93.1) 134	(6.9)  
  Nonsusceptible§ 106	(86.9) 16	(13.1)  
 Erythromycin   0.010 
  Susceptible 1,464	(93.1) 109	(6.9)  
  Nonsusceptible 451	(92.8) 35	(7.2)  
*PCV,	pneumococcal	conjugate	vaccine;	PCV7,	7-valent	PCV;	PCV13,	13-
valent	PCV; 
†Pearson χ2 test. 
‡Serotypes contained in PCV13 but not in PCV7. 
§Either	resistant	or	intermediate	resistance. 
 
Figure 2.	Invasive	
pneumococcal	disease	study	
variables	and	PCV	coverage	
of Streptococcus pneumoniae 
serotypes,	Europe,	2010.	A)	Age	
group.	B)	Clinical	presentation.	
C)	Penicillin	susceptible.	D)	
Erythromycin	susceptible.	For	
all	4	variables,	p<0.001.	White	
bars,	PCV7	serotypes;	gray	
bars,	PCV13	serotypes;	black	
bars,	non-PCV	serotypes.	
PCV,	pneumococcal	conjugate	
vaccine;	PCV7,	7-valent	PCV;	
PCV13,	13-valent	PCV.
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susceptibility to penicillin. As have many other studies, 
we found an association between increased age and death 
(19–22). The risk was higher for adults >65 years of age 
(RR 4.79, 95% CI 3.08–11.76) than for persons 5–64 years 
of age (RR 3.55, 95% CI 1.66–7.61). However, the lack of 
information about patients’ clinical characteristics impedes 
accurate assessments of these differences.
Elderly persons have been postulated to have an in-
creased susceptibility to—in addition to co-ocurring condi-
tions—pneumococcal disease because of reduced splenic 
function (23), age-related changes in respiratory tract, im-
munosenescence, and cellular senescence related to age-as-
sociated inflammation (23). The higher incidence and death 
rates for IPD in this age group is remarkable and highlights 
the need to direct vaccination toward the elderly. These 
findings may present an opportune moment to revisit adult 
vaccination recommendations and programs in European 
countries (24).
We did not find sex to be significantly associated with 
death. However, other studies have shown association ei-
ther with men (25) or women (23,26).
In our study, presence of meningitis was significant-
ly associated with death. Harboe et al. obtained similar 
results in a large population-based cohort study (25). In 
Denmark, another study concluded that patients with 
pneumococcal meningitis had increased death rates, but 
these rates derived from severe underlying conditions 
(27). CFRs for pneumococcal meningitis are usually high-
er than for nonmeningitis (28). More recently, Ladhani 
et al. found that the CFR was higher for children with 
meningitis in England and Wales (29). This study showed 
that infecting serotype was not associated with death (29), 
whereas meningitis and co-occurring conditions were sig-
nificantly associated with death. In our analysis, menin-
gitis was predominantly caused by non-PCV serotypes; 
this finding could be an effect of PCV introduction, as 
observed in other studies (30). Another analysis of sus-
ceptibility to penicillin by clinical presentation showed a 
higher risk for death among persons with nonsusceptible 
IPD than for those with susceptible IPD who had men-
ingitis. Therefore, in the absence of information about 
clinical management of cases and existing co-occurring 
conditions, the association between meningitis and non-
susceptibility to penicillin might be an explanation.
Capsular differences between serotypes affect clinical 
presentation and outcome (10,31,32). These differences are 
in accordance with our study, which found PCV7 serotypes 
were associated with death in the univariable analysis. 
Among children <5 years of age, PCV13-specific serotypes 
were most frequently identified, compared with PCV7 
and non-PCV serotypes, as defined in our study. In 2010, 
PCV13 was already licensed, and many European coun-
tries began moving from PCV7 to the higher-valent vac-
cine, although with different schemes, policies, and dates 
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Table 3. Streptococcus pneumoniae serotype	in	invasive	pneumococcal	disease	and	association	with	death,	Europe,	2010* 
Serotype PCV† Fatal,	% Nonfatal,	% RR	(95%	CI) p value‡ 
3 PCV13-specific§ 13.3 9.6 1.39	(0.88–2.21) 0.161 
4 PCV7 6.1 2.8 2.03 (1.04–3.95) 0.038 
19A PCV13-specific 6.1 7.6 0.80	(0.41–1.57) 0.515 
14 PCV7 5.7 4.6 1.23	(0.78–1.85) 0.369 
7F PCV13-specific 4.9 8.3 0.59	(0.35–1.01) 0.053 
6B PCV7 3.8 1.7 2.01	(0.79–5.16) 0.144 
19F PCV7 3.8 1.9 1.85	(0.93–3.65) 0.078 
22F Non-PCV 3.8 2.8 1.35	(0.89–2.03) 0.157 
9V PCV7 3.4 2.2 1.50	(0.95–2.38) 0.081 
23F PCV7 3.4 2.3 1.42	(0.60–3.32) 0.423 
1 PCV13-specific 3.4 13.1 0.25 (0.13–0.48) <0.001 
11A Non-PCV 2.3 1.1 1.97 (1.33–2.94) 0.001 
10A Non-PCV 2.3 1.4 1.52	(0.86–2.68) 0.147 
6A PCV13-specific 2.3 2.3 1.01	(0.39–2.57) 0.990 
6C Non-PCV 1.9 0.7 2.33	(0.93–5.86) 0.072 
9N Non-PCV 1.9 1.5 1.21	(0.52–2.82) 0.664 
12F Non-PCV 1.9 1.8 1.07	(0.51–2.23) 0.867 
35B Non-PCV 1.5 0.2 4.98 (2.49–9.95) <0.001 
33F Non-PCV 1.5 0.9 1.53	(0.55–4.28) 0.414 
18C PCV7 1.5 1.2 1.23	(0.40–3.76) 0.713 
8 Non-PCV 1.5 3.1 0.59	(0.25–1.06) 0.073 
23A Non-PCV 1.1 0.7 1.51	(0.66–3.45) 0.323 
15A Non-PCV 0.8 0.7 1.05	(0.46–2.43) 0.909 
15B Non-PCV 0.8 1.0 0.79	(0.26–2.41) 0.677 
24F Non-PCV 0.4 0.6 0.69	(0.12–4.09) 0.683 
5 PCV13-specific 0.4 2.6 0.15 (0.09–0.26) <0.001 
*PCV,	pneumococcal	conjugate	vaccine;	PCV7,	7-valent	PCV;	PCV13,	13-valent	PCV;	RR,	relative	risk.	Boldface	indicates	statistical	significance. 
†Classification of serotypes according	to	study	group. 
‡Generalized linear model with log-link	function. 
§Serotypes	contained	in	PCV13	but	not	in	PCV7. 
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of introduction. Nevertheless, these changes are unlikely to 
have affected our study findings because we analyzed data 
from 2010.
After stratification, the highest risk for death among 
children <5 years of age corresponded to non-PCV sero-
types. This finding could be attributed to serotype replace-
ment after pneumococcal vaccination (29,30). Our analysis 
found no differences between penicillin-susceptible and 
-nonsusceptible cases among children <5 years of age and 
non-PCV serotypes subgroup with respect to death. How-
ever, the overall percentage of meningitis cases was high 
(18.5% of the study sample), and meningitis was predomi-
nantly caused by non-PCV serotypes (p<0.001) (Figure 2). 
Hence, vaccines with enhanced serotype coverage (higher 
valency) might be needed to prevent IPD in this age group 
in the near future. 
Among persons 5–64 years of age, the risk for death 
was highest for PCV7 serotypes, which were predominant-
ly nonsusceptible to penicillin (p<0.001) (Figure 2). Re-
ductions in IPD caused by PCV7 serotypes in non–vaccine-
eligible age groups in countries with universal use of PCV7 
might indicate the indirect effect of PCV7 (33). However, 
because vaccine policies differed among European coun-
tries at the time of the study, this indirect effect might not 
be reflected in the pooled data (Table 6).
Serotypes 1, 5, and 7F have been described as hav-
ing high potential for invasiveness (these serotypes are 
carried for a short time) but are associated with milder 
disease and lower CFRs (7,9,19,34). As in those studies, 
we found that serotypes 1 and 5 caused IPD but were not 
associated with death.
Serotype 35B has been reported as nonsusceptible to 
penicillin (35). The subanalysis on susceptibility to penicil-
lin for serotype 35B showed that penicillin nonsusceptibil-
ity did not affect the risk for death for serotype 35B. Never-
theless, the increased risk for death of non-PCV serotypes 
11A and 35B merits further monitoring.
We found penicillin nonsusceptibility to be significantly 
associated with death, as described by others (20,36). Never-
theless, in other large studies, this association was not found 
(21,26,34,37), and the effect of multidrug-resistant strains 
remains to be determined. Conversely, we found that eryth-
romycin nonsusceptibility did not significantly affect death, 
as described by Song et al. (37) and Martens et al. (20). A 
plausible explanation might be the additional benefits of 
macrolides (i.e., their immunomodulatory/antiinflamatory 
properties), which might be important when these drugs are 
used in combination with other therapeutic agents (38).
Antimicrobial resistance to S. pneumoniae is increasing 
in many countries in Europe (17), and the prudent use of 
antibacterial drugs, apart from immunization, is pivotal in 
preventing and controlling IPD. Furthermore, these findings 
underpin the importance of antimicrobial susceptibility test-
ing to assist with the clinical management of cases and to 
provide data on prevalence of antimicrobial resistance.
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Table 5. Stratified	analysis	of	Streptococcus pneumoniae serotype	distribution	in	a	study	of	invasive	pneumococcal	disease,	Europe,	
2010* 
Age	group,	y Survived,	no.	(%) Died	(%) RR	(95%	CI) p	value 
<5     
 PCV13-specific 325	(98.8) 4	(1.2) 1  
 PCV7 104	(97.2) 3	(2.8) 2.31	(0.35–15.02) 0.382 
 Non-PCV 128	(95.5) 6	(4.5) 3.68	(1.27–10.69) 0.017 
5–64     
 PCV13-specific 486	(94.4) 29	(5.6) 1  
 PCV7 186	(84.9) 33	(15.1) 2.68	(1.37–5.23) 0.004 
 Non-PCV 451	(92.4) 37	(7.6) 1.35	(0.64–2.82) 0.429 
>65     
 PCV13-specific 338	(87.8) 47	(12.2) 1  
 PCV7 154	(80.6) 37	(19.4) 1.59	(0.90–2.79) 0.108 
 Non-PCV 464	(87.2) 68	(12.8) 1.05	(0.64–1.72) 0.856 
*PCV,	pneumococcal	conjugate	vaccine;	PCV7,	7-valent	PCV;	PCV13,	13-valent	PCV;	RR,	relative	risk. 
 
 
Table 4. Association	between	invasive	pneumococcal	disease	
study	variables	and	death,	Europe,	2010* 
Variable Relative risk† (95% CI) 
Sex  
 F Reference 
 M 1.06	(0.88–1.28) 
Age	group,	y  
 <5 Reference 
 5–64 3.55	(1.66–7.61) 
 >65 4.79	(3.08–11.76) 
Clinical	presentation  
 Nonmeningitis Reference 
 Meningitis 1.81	(1.25–2.61) 
Serotype  
 PCV13-specific‡ Reference 
 PCV7 2.18	(1.06–4.48) 
 Non-PCV 1.47	(0.94–2.28) 
Antimicrobial	susceptibility  
 Penicillin  
  Susceptible Reference 
  Nonsusceptible§ 1.91	(1.16–3.13) 
 Erythromycin  
  Susceptible Reference 
  Nonsusceptible 1.04	(0.84–1.29) 
*PCV,	pneumococcal	conjugate	vaccine;	PCV7,	7-valent	PCV;	PCV13,	 
13-valent	PCV. 
†Generalized linear model with log-link	function. 
‡Serotypes contained in PCV13 but	not	in	PCV7. 
§Either	resistant	or	intermediate	resistance. 
 
Risk	Factors	for	Death	from	IPD
The major strength of our study is its large sample size; 
data were from national surveillance systems across Europe 
(i.e., we analyzed IPD individual-level data from popula-
tions in a large geographic area). In 2010, European IPD 
surveillance collected data corresponding to ≈82% of the 
total population of EU/European Economic Area countries. 
This enhanced surveillance for IPD data pooled together at 
supranational level enables comparisons with other parts 
of the world.
Despite its strengths, our study has some limitations. 
Surveillance of IPD varies markedly in Europe, includ-
ing differences in laboratory methods to confirm cases, re-
porting, and medical practices. Therefore, a certain degree 
of underdiagnosis and underreporting are likely to exist in 
this dataset. Moreover, surveillance systems for IPD dif-
fer in sensitivity, representativeness, and specificity across 
Europe; these variations might have influenced the results 
because some countries were major contributors (Table 7) 
and ascertainment bias might have also occurred. Informa-
tion about co-occurring conditions or clinical management 
of cases that might have affected outcome was also missing. 
European countries introduced pneumococcal vaccination at 
different times and with different policies, which might have 
affected the serotype distribution throughout Europe. Fur-
thermore, the incomplete information about the vaccination 
status of cases makes difficult the interpretation of results. 
These limitations emphasize the need for continued and im-
proved surveillance of IPD throughout Europe.
In conclusion, we found that older age, meningitis, non-
PCV serotypes among children <5 years of age and PCV7 
serotypes among persons 5–64 years of age, and penicillin 
nonsusceptibility were risk factors for death from IPD in 
Europe. The stratified analysis highlighted differences in 
risk for death according to S. pneumoniae serotype and age 
group. This knowledge may assist in decision making when 
implementing vaccination strategies as new immunization 
strategies are needed to tackle the considerable IPD and as-
sociated death in adults (39) and in designing new extended 
valency vaccines or protein-based pneumococcal vaccines 
that may confer serotype-independent immunity (40).
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Table 6.	Characteristics	of	national	pneumococcal	vaccination	programs	in	European	Union/European	Economic	Area	countries,	
2010* 
Country 
Date	of	PCV7	
introduction 
Scope	of	PCV	
vaccination	
program 
Immunization	
schedule 
Dose 
Vaccine	
coverage† 
Year	of	
measurement 
First,	
mo 
Second,	
mo 
Third,	
mo 
Fourth,	
mo 
Austria 2004	Jul Universal 3+1	dose 3 5 7 12–24 NA NA 
Belgium 2005	Jan Universal 2+1	dose 2 4 12  97 2010 
Bulgaria 2010	Apr Universal 3+1	dose/2+1	
dose 
2 3 4 12 NA NA 
Cyprus 2008	Aug Universal 3+1	dose 2 4 6 12–15 NA NA 
Czech	Republic 2010	Jan Risk-based 3+1	dose 2 4 6 18 86.3 2010 
Denmark 2007	Oct Universal 2+1	dose 3 5 12  85 2010 
Estonia NA NA not	decided NA NA NA NA NA NA 
Finland 2009	Jan Risk-based 2+1	dose 3 5 12  NA NA 
France 2006	Jun Universal 2+1	dose 2 4 12  81 2008 
Germany 2006	Jul Universal 3+1	dose 2 3 4 11–14 52.9 2010 
Greece 2006	Jan Universal 3+1	dose 2 4 6 12–15 NA NA 
Hungary 2008	Oct Universal 2+1	dose 2 4 15  81.1 2009 
Iceland 2006	Dec Risk-based 2+1	dose 3 5 12  NA NA 
Ireland 2002	Oct Universal 2+1	dose 2 6 12  89 2009 
Italy 2005	May Universal/risk- 
based 
2+1	dose 3 5 11  55 2008 
Latvia 2010	Jan Universal 3+1	dose 2 4 6 12–15 51 2010 
Lithuania NA NA 3+1	dose 2 4 6 24 NA NA 
Luxembourg 2003	Feb Universal 3+1	dose 2 3 4 12–15 86 2010 
Malta 2007	Jan Risk-based 3+1	dose 2 4 13 None NA NA 
Netherlands 2006	Jun Universal 3+1	dose 2 3 4 11 94 2009 
Norway 2006	Jul Universal 2+1	dose 3 5 12  90 2009 
Poland 2008	May Risk-based 3+1	dose/2+1	
dose 
NA NA NA NA 1.70 2008 
Portugal 2010	Jun Risk-based 2+1	dose 2 4 12–15  52 2009 
Romania‡   3+1	dose 2 4 6 15–18   
Slovakia§ 2006	Jan Risk-based 2+1	dose 2 4 10  99.2 2009 
Slovenia 2005	Sep Risk-based 3+1	dose 2-3 4 6 24 NA NA 
Spain¶ 2001	Jun Risk-based 3+1	dose 2 4 6 15 NA NA 
Sweden 2009	Jan Universal 2+1	dose 3 5 12  NA NA 
United	Kingdom 2006	Sep Universal 2+1	dose 2 4 13  90 2010 
*NA,	not	available;	PCV,	pneumococcal	conjugate	vaccine;	PCV7,	7-valent	PCV.	Blank	cells	indicate	not	applicable. 
†Sources: Vaccine	European	New	Integrated	Collaboration	Effort	II	project	and	World	Health	Organization	estimates	of	PCV7	coverage. 
‡PCV7 was registered in September 2007 for voluntary use on a private basis. 
§Universal	as	of	April	2008. 
¶Universal	introduction	in	the	autonomous	region	of	Madrid	in	November	2006. 
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